Jaka jest cena za AlloVir, Inc. (ALVR)

Cena za AlloVir, Inc. (ALVR) wynosi $9.81

Jaka jest kapitalizacja rynkowa dla AlloVir, Inc. (ALVR)

Kapitalizacja rynkowa dla AlloVir, Inc. (ALVR) wynosi $48.68M

Zyski AlloVir, Inc. (ALVR)

AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.

Rok	Zyski	Zmień
2026 (TTM)	$-54.46M	-7.33%
2024	$-58.77M	-69.16%
2023	$-190.54M	12.76%
2022	$-168.98M	-1.16%
2021	$-170.96M	144.98%
2020	$-69.78M	192.73%
2019	$-23.84M	881.03%
2018	$-2.43M	0.00%

Rok

Zyski

Zmień

2026 (TTM)

$-54.46M

-7.33%

2024

$-58.77M

-69.16%

2023

$-190.54M

12.76%

2022

$-168.98M

-1.16%

2021

$-170.96M

144.98%

2020

$-69.78M

192.73%

2019

$-23.84M

881.03%

2018

$-2.43M

0.00%

Firma	Zyski	Różnica w zyskach	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-9,786.00%	US
Argenx SE ARGX.US	$1.95B	-3,681.87%	NL
CSL Limited CSL.AX	$1.61B	-3,064.22%	AU
Lonza Group AG LONN.SW	-	-	CH
Moderna, Inc. MRNA.US	$-3.09B	5,568.48%	US

Firma

Zyski

Różnica w zyskach

Kraj